2023 World Conference on Lung Cancer (Posters)-P1.17. Lung-Cancer Screening: Is It Worth Investing? Evidence from a Population-Based Markov Study in Italy

Pdf Summary

A population-based lung cancer screening program targeting high-risk heavy smokers in Italy has been found to be cost-effective, according to a Markov study. The study used a dynamic cohort-based model to analyze the cost-effectiveness of four specific LDCT-based screening invitation scenarios compared to standard clinical care. The results showed that the incremental gain in quality-adjusted life years (QALYs) ranged from 52,141 to 81,236, with an incremental budget impact ranging from 771 million to 1.3 billion over 15 years. The incremental cost-effectiveness ratios (ICERs) for the LDCT-based screening scenarios varied between 14,527 and 16,040 per QALY gained compared to standard care. These findings suggest that population-based LDCT lung cancer screening programs are cost-effective in Italy.<br /><br />The study provides robust support for policy makers, payers, and guideline developers who are considering implementing lung cancer screening programs. The results are consistent with previous research that has shown the effectiveness of low-dose computed tomography (LDCT) screening in reducing lung cancer mortality. The study also highlights the importance of targeting high-risk individuals, such as heavy smokers, for screening. <br /><br />The findings have significant implications for healthcare decision-making in Italy and provide valuable evidence for the potential benefits of implementing population-based lung cancer screening programs. Such programs have the potential to save lives by detecting lung cancer at an earlier stage when treatment outcomes are more favorable. The study's cost-effectiveness analysis reinforces the argument for investing resources in lung cancer screening, as it offers a favorable incremental cost-effectiveness ratio compared to standard clinical care.<br /><br />In conclusion, the study demonstrates that population-based LDCT lung cancer screening is cost-effective in Italy, providing support for the implementation of life-saving screening programs. The findings contribute to the growing body of evidence on the benefits of lung cancer screening and have important implications for healthcare policy and decision-making.

Asset Subtitle

Pierluigi Novellis

Meta Tag

Speaker Pierluigi Novellis

Topic Screening & Early Detection: Program Design

Keywords

lung cancer screening

Italy

cost-effectiveness

Markov study

LDCT-based screening

QALYs

incremental budget impact

high-risk individuals

healthcare decision-making

screening programs